0001179929-16-000219.txt : 20160208 0001179929-16-000219.hdr.sgml : 20160208 20160208161903 ACCESSION NUMBER: 0001179929-16-000219 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20160208 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160208 DATE AS OF CHANGE: 20160208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOLINA HEALTHCARE INC CENTRAL INDEX KEY: 0001179929 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 134204626 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31719 FILM NUMBER: 161395877 BUSINESS ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 BUSINESS PHONE: 5624353666 MAIL ADDRESS: STREET 1: 200 OCEANGATE, SUITE 100 CITY: LONG BEACH STATE: CA ZIP: 90802 8-K 1 moh4q15123120158k.htm 8-K 8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 8, 2016
______________
MOLINA HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)
Delaware
1-31719
13-4204626
(State of incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
______________
200 Oceangate, Suite 100, Long Beach, California 90802
(Address of principal executive offices)
Registrant’s telephone number, including area code: (562) 435-3666

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 2.02.    Results of Operations and Financial Condition.
On February 8, 2016, Molina Healthcare, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2015. The full text of the press release is included as Exhibit 99.1 to this report. The information contained in the websites cited in the press release is not part of this report.
The information in this Form 8-K and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01.    Financial Statements and Exhibits.
(d)     Exhibits:
Exhibit
No.               Description
99.1              Press release of Molina Healthcare, Inc. issued February 8, 2016, as to financial results for the fourth quarter and year ended December 31, 2015.





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MOLINA HEALTHCARE, INC.
 
 
 
Date:
February 8, 2016
By:
/s/ Jeff D. Barlow
 
 
Jeff D. Barlow
 
 
Chief Legal Officer and Secretary





EXHIBIT INDEX
Exhibit
 
No.
Description
 
 
99.1
Press release of Molina Healthcare, Inc. issued February 8, 2016, as to financial results for the fourth quarter and year ended December 31, 2015.


EX-99.1 2 moh4q1512312015.htm EXHIBIT 99.1 Exhibit



News Release

Contact:
Juan José Orellana
Investor Relations
562-435-3666, ext. 111143


MOLINA HEALTHCARE REPORTS
FOURTH QUARTER AND YEAR-END 2015 RESULTS

Full year 2015 net income per diluted share of $2.57, up nearly 100% over 2014.
Full year 2015 total revenue of $14.1 billion, up 46% over 2014.
Aggregate membership up 35% over 2014.
Excluding a contract settlement charge of $0.16 per diluted share, diluted net income per share for the fourth quarter of 2015 would have been $0.67 compared with $0.69 for the fourth quarter of 2014.

Long Beach, California (February 8, 2016) - Molina Healthcare, Inc. (NYSE: MOH) today reported its financial results for the fourth quarter of 2015.
“The fourth quarter of 2015 capped off a very strong year for Molina Healthcare. Net income more than doubled compared with 2014, and we are making progress toward our goal of a 1.5% to 2% net income margin by the end of 2017,” said J. Mario Molina M.D., chief executive officer of Molina Healthcare, Inc. “The in-market ‘tuck-in’ acquisitions already announced give us strong momentum going into 2016 and complement the already strong revenue growth we experienced over the past two years. I want to thank all of our employees for a great year.”
2016 Business Outlook and Investor Meeting
As has been the Company’s past practice, it will discuss its 2016 business outlook and strategy at its Investor Day Conference webcast and presentation to be held on February 11, 2016, at the Le Parker Meridien Hotel in New York City from 12:30 p.m. to 4:30 p.m. Eastern Time. The Company will webcast the presentations offered by its management team, which will be followed by question-and-answer sessions. A 30-day online replay of the Investor Day meeting will be available approximately one hour following the conclusion of the live webcast. A link to this webcast can be found on the Company’s website at molinahealthcare.com.
Overview of 2015 Financial Results, Continuing Operations
Earnings per diluted share nearly doubled in 2015 when compared with 2014, while net income more than doubled. Substantial increases in revenue, along with improved operating efficiency, were responsible for

-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 2
February 8, 2016

the Company’s improved performance. The Company’s after-tax margin increased to 1.0% in 2015 from 0.6% in 2014.
Strong enrollment growth combined with a 4% increase in premium revenue per member generated over $4 billion, or 46% more premium revenue in 2015 compared with 2014.
Enrollment growth was primarily due to increased Medicaid Expansion, Marketplace and integrated Medicare-Medicaid Plan (MMP) enrollment, and the start-up of the Puerto Rico health plan in April 2015.
Medical care costs as a percent of premium revenue (the “medical care ratio”) decreased to 89.0% in 2015, from 89.5% in 2014.
General and administrative expenses as a percentage of total revenue (the “general and administrative expense ratio”) increased slightly to 8.2% in 2015, from 7.9% in 2014, primarily as a result of dramatic growth in the Company’s Marketplace membership. Excluding Marketplace broker and exchange fees from both years, the general and administrative expense ratio decreased to 7.5% in 2015 from 7.8% in 2014.
Other items affecting premium revenue in 2015 included the Affordable Care Act health insurer fee (HIF). During 2015, the Company secured full reimbursement for its expenses under the HIF. Additionally, as the Company has previously disclosed, it has been unable to recognize certain quality related revenue at its Texas health plan because it does not have historical information, clear definitions, and clarity around minimum standards. The Company recognized no such revenue in either the fourth quarter of 2015, or the year as a whole.
Fourth Quarter Developments
Fourth quarter results were favorable for the reasons explained above. The following items are included in results for the fourth quarter of 2015:
During the quarter, the Company recorded a contract settlement charge of approximately $15 million ($0.16 per diluted share) as a result of its termination of a hospital management agreement.
During the fourth quarter of 2015, the Company recognized approximately $6 million ($0.07 per diluted share) of interest expense related to $700 million of senior notes due 2022 issued in November.
General and administrative expense for the fourth quarter 2015 includes approximately $3 million ($0.03 per diluted share) in transaction costs for business acquisitions.
Conference Call
The Company’s management will host a conference call and webcast to discuss its fourth quarter and year-end results at 5:00 p.m. Eastern time on Monday, February 8, 2016. The number to call for the interactive teleconference is (212) 271-4657. A telephonic replay of the conference call will be available from 7:00 p.m. Eastern time on Monday, February 8, 2016, through 6:00 p.m. on Tuesday, February 9, 2016, by dialing (800) 633-8284 and entering confirmation number 21802135. A live audio broadcast of Molina Healthcare’s conference call will be available on the Company’s website, molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed health care services under the Medicaid and Medicare programs and through the state insurance marketplaces. Through our locally operated health plans in 11 states across the nation and in the Commonwealth of Puerto Rico, Molina currently serves approximately 3.5 million members. Dr. C. David Molina founded our company in 1980 as a provider organization serving low-income families in Southern California. Today, we continue his mission of providing high quality and cost-effective health care to those who need it most. For more information about Molina Healthcare, please visit our website at molinahealthcare.com.

-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 3
February 8, 2016

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This earnings release contains “forward-looking statements” regarding the Company’s plans, expectations, and anticipated future events. Actual results could differ materially due to numerous known and unknown risks and uncertainties. Those known risks and uncertainties include, but are not limited, to the following:
uncertainties and evolving market and provider economics associated with the implementation of the Affordable Care Act, the Medicaid expansion, the insurance marketplaces, the effect of various implementing regulations, and uncertainties regarding the Medicare-Medicaid dual eligible demonstration programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas;
management of our medical costs, including seasonal flu patterns and rates of utilization that are consistent with our expectations, and our ability to reduce over time the high medical costs commonly associated with new patient populations;
federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit sharing arrangements, and conflicting interpretations thereof;
the interpretation and implementation of at-risk premium rules regarding the achievement of certain quality measures;
cyber-attacks or other privacy or data security incidents resulting in an inadvertent unauthorized disclosure of protected health information;
the success of our new health plan in Puerto Rico, including the successful resolution of the Puerto Rico debt crisis and the payment of all amounts due under our Medicaid contract;
specialty drugs or generic drugs that are exorbitantly priced but not factored into the calculation of our capitated rates;
significant budget pressures on state governments and their potential inability to maintain current rates, to implement expected rate increases, or to maintain existing benefit packages or membership eligibility thresholds or criteria, including the resolution of the Illinois budget impasse and continued payment of our Illinois health plan;
the accurate estimation of incurred but not reported or paid medical costs across our health plans;
retroactive adjustments to premium revenue or accounting estimates which require adjustment based upon subsequent developments;
efforts by states to recoup previously paid amounts;
the success of our efforts to retain existing government contracts and to obtain new government contracts in connection with state requests for proposals (RFPs) in both existing and new states;
the continuation and renewal of the government contracts of both our health plans and Molina Medicaid Solutions and the terms under which such contracts are renewed;
complications, member confusion, or enrollment backlogs related to the annual renewal of Medicaid coverage;
government audits and reviews, and any fine, enrollment freeze, or monitoring program that may result therefrom;
changes with respect to our provider contracts and the loss of providers;
approval by state regulators of dividends and distributions by our health plan subsidiaries;
changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;
high dollar claims related to catastrophic illness;
the favorable resolution of litigation, arbitration, or administrative proceedings;
the relatively small number of states in which we operate health plans;
the effect on our Los Angeles County subcontract of Centene’s acquisition of Health Net;
the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity and meet our liquidity needs, including the interest expense and other costs associated with such financing;
the failure of a state in which we operate to renew its federal Medicaid waiver;
changes generally affecting the managed care or Medicaid management information systems industries;
increases in government surcharges, taxes, and assessments;
newly emergent viruses or widespread epidemics, including the Zika virus, and associated public alarm;
changes in general economic conditions, including unemployment rates;
the sufficiency of our funds, on hand to pay the amounts due upon conversion of our outstanding notes;
increasing competition and consolidation in the Medicaid industry;
and numerous other risk factors, including those discussed in the Company’s periodic reports and filings with the Securities and Exchange Commission. These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, we can give no assurances that the Company’s forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by the Company’s forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of February 8, 2016, and we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in the Company’s expectations.



-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 4
February 8, 2016

MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
 
Three Months Ended
 
Year Ended
 
December 31,
 
December 31,
 
2015
 
2014
 
2015
 
2014
 
(Dollar amounts in millions, except net income per share)
Revenue:
 
 
 
 
 
 
 
Premium revenue
$
3,488

 
$
2,599

 
$
13,140

 
$
9,023

Service revenue
106

 
54

 
252

 
210

Premium tax revenue
104

 
91

 
393

 
294

Health insurer fee revenue
61

 
52

 
264

 
120

Investment income
6

 
2

 
18

 
8

Other revenue

 
4

 
5

 
12

Total revenue
3,765

 
2,802

 
14,072

 
9,667

Operating expenses:
 
 
 
 
 
 
 
Medical care costs
3,110

 
2,322

 
11,691

 
8,076

Cost of service revenue
90

 
39

 
193

 
157

General and administrative expenses
317

 
205

 
1,147

 
765

Premium tax expenses
104

 
91

 
393

 
294

Health insurer fee expenses
40

 
23

 
157

 
89

Depreciation and amortization
28

 
25

 
104

 
93

Total operating expenses
3,689

 
2,705

 
13,685

 
9,474

Operating income
76

 
97

 
387

 
193

Other expenses, net:
 
 
 
 
 
 
 
Interest expense
22

 
15

 
67

 
57

Other (income) expense, net
(2
)
 

 
(2
)
 
1

Total other expenses, net
20

 
15

 
65

 
58

Income from continuing operations before income tax expense
56

 
82

 
322

 
135

Income tax expense
26

 
48

 
179

 
73

Income from continuing operations
30

 
34

 
143

 
62

Net income
$
30

 
$
34

 
$
143

 
$
62

 
 
 
 
 
 
 
 
Diluted net income per share: (1)
 
 
 
 
 
 
 
Income from continuing operations
$
0.51

 
$
0.69

 
$
2.57

 
$
1.30

Loss from discontinued operations

 

 

 
(0.01
)
Diluted net income per share
$
0.51

 
$
0.69

 
$
2.57

 
$
1.29

 
 
 
 
 
 
 
 
Diluted weighted average shares outstanding
57.7

 
48.9

 
55.6

 
48.3

 
 
 
 
 
 
 
 
Operating Statistics, Continuing Operations: (1)
 
 
 
 
 
 
 
Medical care ratio (2)
89.2
%
 
89.4
%
 
89.0
%
 
89.5
%
Service revenue ratio (3)
84.7
%
 
72.6
%
 
76.4
%
 
74.6
%
General and administrative expense ratio (4)
8.4
%
 
7.3
%
 
8.2
%
 
7.9
%
Premium tax ratio (2)
2.9
%
 
3.4
%
 
2.9
%
 
3.2
%
Effective tax rate
47.0
%
 
58.6
%
 
55.5
%
 
53.8
%
Net profit margin, continuing operations (4)
0.8
%
 
1.2
%
 
1.0
%
 
0.6
%
____________
(1)
Source data for calculations in thousands.
(2)
Medical care ratio represents medical care costs as a percentage of premium revenue; premium tax ratio represents premium tax expenses as a percentage of premium revenue plus premium tax revenue. Medical care costs include costs incurred for providing long term services and supports (LTSS).
(3) Service revenue ratio represents cost of service revenue as a percentage of service revenue.
(4)
Computed as a percentage of total revenue.

-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 5
February 8, 2016

MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED BALANCE SHEETS
 
December 31,
 
2015
 
2014
 
(Amounts in millions,
except per-share data)
ASSETS
Current assets:
 
 
 
Cash and cash equivalents
$
2,329

 
$
1,539

Investments
1,801

 
1,019

Receivables
597

 
596

Income taxes refundable
13

 

Prepaid expenses and other current assets
192

 
49

Derivative asset
374

 

Total current assets
5,306

 
3,203

Property, equipment, and capitalized software, net
393

 
341

Deferred contract costs
81

 
54

Intangible assets, net
122

 
89

Goodwill
519

 
272

Restricted investments
109

 
102

Derivative asset

 
329

Deferred income taxes
18

 
15

Other assets
28

 
30

 
$
6,576

 
$
4,435

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
 
 
 
Medical claims and benefits payable
$
1,582

 
$
1,201

Amounts due government agencies
834

 
527

Accounts payable and accrued liabilities
360

 
242

Deferred revenue
223

 
196

Income taxes payable

 
9

Current portion of long-term debt
449

 

Derivative liability
374

 

Total current liabilities
3,822

 
2,175

Senior notes
962

 
690

Lease financing obligations
198

 
157

Lease financing obligations - related party

 
40

Derivative liability

 
329

Other long-term liabilities
37

 
34

Total liabilities
5,019

 
3,425

Stockholders’ equity:
 
 
 
Common stock, $0.001 par value; 150 shares authorized; outstanding: 56 shares at December 31, 2015 and 50 shares at December 31, 2014

 

Preferred stock, $0.001 par value; 20 shares authorized, no shares issued and outstanding

 

Additional paid-in capital
803

 
396

Accumulated other comprehensive loss
(4
)
 
(1
)
Retained earnings
758

 
615

Total stockholders’ equity
1,557

 
1,010

 
$
6,576

 
$
4,435

____________
Note: Certain 2014 amounts have been reclassified to conform to the 2015 presentation. Specifically, current and non-current deferred issuance costs are now reported as direct deductions from “Current portion of long-term debt,” and “Senior notes,” respectively. Additionally, the aggregate amount of deferred income taxes are now reported as non-current. Both reclassifications are a result of recently adopted accounting pronouncements.

-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 6
February 8, 2016

MOLINA HEALTHCARE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS,
CONTINUING AND DISCONTINUED OPERATIONS
 
Three Months Ended
 
Year Ended
 
December 31,
 
December 31,
 
2015
 
2014
 
2015
 
2014
 
(Amounts in millions)
Operating activities:
 
 
 
 
 
 
 
Net income
$
30

 
$
34

 
$
143

 
$
62

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
 
 
Depreciation and amortization
33

 
35

 
126

 
134

Deferred income taxes
5

 
9

 
(7
)
 
(2
)
Share-based compensation
7

 
6

 
23

 
22

Amortization of convertible senior notes and lease financing obligations
8

 
7

 
30

 
27

Other, net
6

 
3

 
19

 
7

Changes in operating assets and liabilities:
 
 
 
 
 
 
 
Receivables
79

 
(171
)
 
56

 
(298
)
Prepaid expenses and other current assets
28

 
32

 
(35
)
 
(20
)
Medical claims and benefits payable
20

 
77

 
379

 
531

Amounts due government agencies
(146
)
 
129

 
307

 
470

Accounts payable and accrued liabilities
48

 
37

 
82

 
11

Deferred revenue
153

 
5

 
24

 
74

Income taxes
(52
)
 
17

 
(22
)
 
42

Net cash provided by operating activities
219

 
220

 
1,125

 
1,060

 
 
 
 
 
 
 
 
Investing activities:
 
 
 
 
 
 
 
Purchases of investments
(612
)
 
(337
)
 
(1,923
)
 
(953
)
Proceeds from sales and maturities of investments
263

 
159

 
1,126

 
633

Purchases of property, equipment, and capitalized software
(31
)
 
(43
)
 
(132
)
 
(115
)
Increase in restricted investments
(1
)
 
(10
)
 
(6
)
 
(34
)
Net cash paid in business combinations
(373
)
 
(36
)
 
(450
)
 
(44
)
Other, net
(1
)
 
(8
)
 
(35
)
 
(23
)
Net cash used in investing activities
(755
)
 
(275
)
 
(1,420
)
 
(536
)
 
 
 
 
 
 
 
 
Financing activities:
 
 
 
 
 
 
 
Proceeds from senior notes offerings, net of issuance costs
689

 

 
689

 
123

Proceeds from common stock offering, net of issuance costs

 

 
373

 

Contingent consideration liabilities settled

 

 

 
(50
)
Proceeds from employee stock plans
10

 
6

 
18

 
14

Principal payments on convertible senior notes

 
(10
)
 

 
(10
)
Other, net
2

 

 
5

 
2

Net cash provided by (used in) financing activities
701

 
(4
)
 
1,085

 
79

Net increase (decrease) in cash and cash equivalents
165

 
(59
)
 
790

 
603

Cash and cash equivalents at beginning of period
2,164

 
1,598

 
1,539

 
936

Cash and cash equivalents at end of period
$
2,329

 
$
1,539

 
$
2,329

 
$
1,539


-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 7
February 8, 2016

MOLINA HEALTHCARE, INC.
UNAUDITED NON-GAAP FINANCIAL MEASURES
The Company uses two non-GAAP financial measures as supplemental metrics in evaluating its financial performance, making financing and business decisions, and forecasting and planning for future periods. For these reasons, management believes such measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. These non-GAAP financial measures should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.

The first of these non-GAAP measures is earnings before interest, taxes, depreciation and amortization (EBITDA). The following table reconciles net income, which the Company believes to be the most comparable GAAP measure, to EBITDA.
 
Three Months Ended
 
Year Ended
 
December 31,
 
December 31,
 
2015
 
2014
 
2015
 
2014
 
(Amounts in millions)
Net income
$
30

 
$
34

 
$
143

 
$
62

Adjustments:
 
 
 
 
 
 
 
Depreciation, and amortization of intangible assets and capitalized software
33

 
30

 
120

 
114

Interest expense
22

 
15

 
67

 
57

Income tax expense
26

 
48

 
179

 
72

EBITDA
$
111

 
$
127

 
$
509

 
$
305

The second of these non-GAAP measures is adjusted net income, continuing operations (including adjusted net income per diluted share). The following table reconciles net income from continuing operations, which the Company believes to be the most comparable GAAP measure, to adjusted net income, continuing operations. The source data for per diluted share calculations below is in thousands.
 
Three Months Ended December 31,
 
Year Ended December 31,
2015
 
2014
 
2015
 
2014
 
(In millions, except per diluted share amounts)
 
Amount
 
Per share
 
Amount
 
Per share
 
Amount
 
Per share
 
Amount
 
Per share
Net income, continuing operations
$
30

 
$
0.51

 
$
34

 
$
0.69

 
$
143

 
$
2.57

 
$
62

 
$
1.30

Adjustments, net of tax:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amortization of convertible senior notes and lease financing obligations
5

 
0.08

 
4

 
0.09

 
19

 
0.34

 
17

 
0.36

Amortization of intangible assets
3

 
0.06

 
3

 
0.06

 
11

 
0.20

 
13

 
0.27

Adjusted net income, continuing operations (1)
$
38

 
$
0.65

 
$
41

 
$
0.84

 
$
173

 
$
3.11

 
$
92

 
$
1.93

________________________

(1)
Beginning in the first quarter of 2015, the Company revised its calculation of adjusted net income, continuing operations. The Company no longer subtracts depreciation, and amortization of capitalized software and share-based compensation from net income, continuing operations to arrive at adjusted net income, continuing operations. The Company made this change to better reflect the way in which it evaluates its financial performance, makes financing and business decisions, and forecasts and plans for future periods. All periods presented conform to this presentation.


-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 8
February 8, 2016

MOLINA HEALTHCARE, INC.
UNAUDITED HEALTH PLANS SEGMENT MEMBERSHIP, CONTINUING OPERATIONS
 
As of December 31,
 
2015
 
2014
 
2013
Ending Membership by Health Plan:
 
 
 
 
 
California
620,000

 
531,000

 
368,000

Florida
440,000

 
164,000

 
89,000

Illinois
98,000

 
100,000

 
4,000

Michigan
328,000

 
242,000

 
213,000

New Mexico
231,000

 
212,000

 
168,000

Ohio
327,000

 
347,000

 
255,000

Puerto Rico (1)
348,000

 

 

South Carolina
99,000

 
118,000

 

Texas
260,000

 
245,000

 
252,000

Utah
102,000

 
83,000

 
86,000

Washington
582,000

 
497,000

 
403,000

Wisconsin
98,000

 
84,000

 
93,000

 
3,533,000

 
2,623,000

 
1,931,000

Ending Membership by Program:
 
 
 
 
 
Temporary Assistance for Needy Families (TANF), CHIP(2)
2,312,000

 
1,809,000

 
1,603,000

Medicaid Expansion(3)
557,000

 
385,000

 

Aged, Blind or Disabled (ABD)
366,000

 
347,000

 
289,000

Marketplace(3)
205,000

 
15,000

 

Medicare-Medicaid Plan (MMP) - Integrated(4)
51,000

 
18,000

 

Medicare Special Needs Plans
42,000

 
49,000

 
39,000

 
3,533,000

 
2,623,000

 
1,931,000

_______________________
(1)
The Puerto Rico health plan began serving members effective April 1, 2015.
(2)
CHIP stands for Children’s Health Insurance Program.
(3)
Medicaid Expansion membership phased in, and Marketplace became available for consumers to access coverage, beginning January 1, 2014.
(4)
MMP members who receive both Medicaid and Medicare coverage from the Company. The Company began serving members under this program in the second quarter of 2014.



-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 9
February 8, 2016


MOLINA HEALTHCARE, INC.
UNAUDITED SELECTED HEALTH PLANS SEGMENT FINANCIAL DATA,
CONTINUING OPERATIONS
(In millions, except percentages and per-member per-month amounts)
 
Three Months Ended December 31, 2015
 
Member
Months(1)
 
Premium Revenue
 
Medical Care Costs
 
MCR(2)
 
Medical Margin
 
 
Total
 
PMPM
 
Total
 
PMPM
 
 
California
1.8

 
$
563

 
$
309.31

 
$
474

 
$
260.44

 
84.2
%
 
$
89

Florida
1.2

 
329

 
277.71

 
318

 
268.98

 
96.9

 
11

Illinois
0.3

 
85

 
287.88

 
79

 
266.91

 
92.7

 
6

Michigan
1.0

 
329

 
334.44

 
282

 
287.00

 
85.8

 
47

New Mexico
0.7

 
304

 
438.82

 
263

 
379.10

 
86.4

 
41

Ohio
1.0

 
500

 
501.11

 
437

 
436.77

 
87.2

 
63

Puerto Rico
1.1

 
192

 
184.79

 
159

 
153.04

 
82.8

 
33

South Carolina
0.3

 
78

 
261.07

 
69

 
229.48

 
87.9

 
9

Texas
0.7

 
543

 
693.06

 
496

 
633.77

 
91.4

 
47

Utah
0.4

 
89

 
290.05

 
77

 
251.55

 
86.7

 
12

Washington
1.7

 
416

 
241.28

 
376

 
217.77

 
90.3

 
40

Wisconsin
0.3

 
55

 
186.57

 
53

 
182.41

 
97.8

 
2

Other(3)

 
5

 

 
27

 

 

 
(22
)
 
10.5

 
$
3,488

 
$
334.62

 
$
3,110

 
$
298.43

 
89.2
%
 
$
378

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended December 31, 2014
 
Member
Months(1)
 
Premium Revenue
 
Medical Care Costs
 
MCR(2)
 
Medical Margin
 
Total
 
PMPM
 
Total
 
PMPM
 
 
California
1.6

 
$
463

 
$
291.27

 
$
379

 
$
238.49

 
81.9
%
 
$
84

Florida
0.4

 
126

 
348.60

 
129

 
356.76

 
102.3

 
(3
)
Illinois
0.2

 
84

 
353.71

 
78

 
323.76

 
91.5

 
6

Michigan
0.7

 
213

 
294.14

 
185

 
254.41

 
86.5

 
28

New Mexico
0.7

 
299

 
456.40

 
294

 
448.99

 
98.4

 
5

Ohio
1.1

 
492

 
475.15

 
426

 
412.02

 
86.7

 
66

Puerto Rico

 

 

 

 

 

 

South Carolina
0.4

 
93

 
263.97

 
73

 
208.10

 
78.8

 
20

Texas
0.8

 
339

 
458.42

 
299

 
404.88

 
88.3

 
40

Utah
0.2

 
76

 
300.28

 
69

 
277.44

 
92.4

 
7

Washington
1.4

 
364

 
246.91

 
342

 
232.08

 
94.0

 
22

Wisconsin
0.2

 
38

 
148.99

 
36

 
139.75

 
93.8

 
2

Other(3)

 
12

 

 
12

 

 

 

 
7.7

 
$
2,599

 
$
338.52

 
$
2,322

 
$
302.60

 
89.4
%
 
$
277

____________
(1)
A member month is defined as the aggregate of each month’s ending membership for the period presented.
(2)
The MCR represents medical costs as a percentage of premium revenue. Source data in thousands.
(3)
“Other” medical care costs include primarily medically related administrative costs at the parent company, and direct delivery costs.





-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 10
February 8, 2016


MOLINA HEALTHCARE, INC.
UNAUDITED SELECTED HEALTH PLANS SEGMENT FINANCIAL DATA,
CONTINUING OPERATIONS
(In millions, except percentages and per-member per-month amounts)
 
Year Ended December 31, 2015
 
Member
Months(1)
 
Premium Revenue
 
Medical Care Costs
 
MCR(2)
 
Medical Margin
 
 
Total
 
PMPM
 
Total
 
PMPM
 
 
California
7.1

 
$
2,101

 
$
296.93

 
$
1,823

 
$
257.67

 
86.8
%
 
$
278

Florida
4.1

 
1,197

 
289.38

 
1,081

 
261.49

 
90.4

 
116

Illinois
1.2

 
397

 
328.93

 
367

 
303.72

 
92.3

 
30

Michigan
3.4

 
1,067

 
317.15

 
903

 
268.27

 
84.6

 
164

New Mexico
2.8

 
1,237

 
446.27

 
1,106

 
398.98

 
89.4

 
131

Ohio
4.1

 
2,034

 
499.34

 
1,718

 
421.61

 
84.4

 
316

Puerto Rico
3.2

 
567

 
178.31

 
505

 
158.80

 
89.1

 
62

South Carolina
1.3

 
348

 
267.25

 
278

 
213.30

 
79.8

 
70

Texas
3.1

 
1,961

 
621.25

 
1,809

 
573.32

 
92.3

 
152

Utah
1.2

 
331

 
286.22

 
300

 
259.32

 
90.6

 
31

Washington
6.6

 
1,602

 
242.36

 
1,470

 
222.36

 
91.7

 
132

Wisconsin
1.2

 
261

 
213.48

 
215

 
176.01

 
82.4

 
46

Other(3)

 
37

 

 
116

 

 

 
(79
)
 
39.3

 
$
13,140

 
$
334.71

 
$
11,691

 
$
297.81

 
89.0
%
 
$
1,449

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Ended December 31, 2014
 
Member
Months(1)
 
Premium Revenue
 
Medical Care Costs
 
MCR(2)
 
Medical Margin
 
Total
 
PMPM
 
Total
 
PMPM
 
 
California
5.6

 
$
1,523

 
$
270.51

 
$
1,269

 
$
225.37

 
83.3
%
 
$
254

Florida
1.1

 
439

 
397.79

 
419

 
379.95

 
95.5

 
20

Illinois
0.3

 
153

 
498.48

 
141

 
456.88

 
91.7

 
12

Michigan
2.8

 
781

 
278.68

 
661

 
235.81

 
84.6

 
120

New Mexico
2.5

 
1,076

 
435.17

 
996

 
402.92

 
92.6

 
80

Ohio
3.7

 
1,553

 
425.47

 
1,335

 
365.87

 
86.0

 
218

Puerto Rico

 

 

 

 

 

 

South Carolina
1.5

 
381

 
260.72

 
323

 
220.89

 
84.7

 
58

Texas
3.0

 
1,318

 
442.32

 
1,197

 
401.81

 
90.8

 
121

Utah
1.0

 
310

 
310.64

 
285

 
286.43

 
92.2

 
25

Washington
5.5

 
1,305

 
236.27

 
1,219

 
220.75

 
93.4

 
86

Wisconsin
1.0

 
156

 
150.87

 
136

 
130.91

 
86.8

 
20

Other(3)

 
28

 

 
95

 

 

 
(67
)
 
28.0

 
$
9,023

 
$
322.68

 
$
8,076

 
$
288.84

 
89.5
%
 
$
947

____________
(1)
A member month is defined as the aggregate of each month’s ending membership for the period presented.
(2)
The MCR represents medical costs as a percentage of premium revenue. Source data in thousands.
(3)
“Other” medical care costs include primarily medically related administrative costs at the parent company, and direct delivery costs.




-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 11
February 8, 2016


MOLINA HEALTHCARE, INC.
UNAUDITED SELECTED HEALTH PLANS SEGMENT FINANCIAL DATA,
CONTINUING OPERATIONS
(In millions, except percentages and per-member per-month amounts)

 
Three Months Ended December 31, 2015 (1)
 
Member
Months(2)
 
Premium Revenue
 
Medical Care Costs
 
MCR(3)
 
Medical Margin
 
 
Total
 
PMPM
 
Total
 
PMPM
 
 
TANF and CHIP
6.9

 
$
1,203

 
$
175.96

 
$
1,092

 
$
159.83

 
90.8
%
 
$
111

Medicaid Expansion
1.7

 
637

 
386.27

 
503

 
305.28

 
79.0

 
134

ABD
1.1

 
1,059

 
967.72

 
995

 
910.11

 
94.0

 
64

Marketplace
0.6

 
126

 
223.57

 
111

 
194.80

 
87.1

 
15

MMP
0.1

 
330

 
2,160.91

 
290

 
1,905.00

 
88.2

 
40

Medicare
0.1

 
133

 
1,076.00

 
119

 
954.40

 
88.7

 
14

 
10.5

 
$
3,488

 
$
334.62

 
$
3,110

 
$
298.43

 
89.2
%
 
$
378


 
Year Ended December 31, 2015 (1)
 
Member
Months(2)
 
Premium Revenue
 
Medical Care Costs
 
MCR(3)
 
Medical Margin
 
 
Total
 
PMPM
 
Total
 
PMPM
 
 
TANF and CHIP
25.5

 
$
4,483

 
$
175.64

 
$
4,122

 
$
161.50

 
92.0
%
 
$
361

Medicaid Expansion
5.9

 
2,291

 
391.62

 
1,828

 
312.58

 
79.8

 
463

ABD
4.3

 
4,122

 
966.37

 
3,784

 
887.27

 
91.8

 
338

Marketplace
2.6

 
651

 
251.96

 
481

 
185.85

 
73.8

 
170

MMP
0.5

 
1,063

 
2,033.76

 
974

 
1,863.93

 
91.6

 
89

Medicare
0.5

 
530

 
1,038.15

 
502

 
982.50

 
94.6

 
28

 
39.3

 
$
13,140

 
$
334.71

 
$
11,691

 
$
297.81

 
89.0
%
 
$
1,449

_______________________
(1)
Three and twelve months ended December 31, 2014 data not presented due to lack of comparability.
(2)
A member month is defined as the aggregate of each month’s ending membership for the period presented.
(3)
The MCR represents medical costs as a percentage of premium revenue. Source data in thousands.


















-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 12
February 8, 2016

MOLINA HEALTHCARE, INC.
UNAUDITED SELECTED HEALTH PLANS SEGMENT FINANCIAL DATA,
CONTINUING OPERATIONS
(In millions, except percentages and per-member per-month amounts)

The following tables provide the details of the Company’s medical care costs from continuing operations for the periods indicated:
 
Three Months Ended December 31,
 
2015
 
2014
 
Amount
 
PMPM
 
% of
Total
 
Amount
 
PMPM
 
% of
Total
Fee for service
$
2,297

 
$
220.34

 
73.9
%
 
$
1,644

 
$
214.14

 
70.8
%
Pharmacy
449

 
43.08

 
14.4

 
354

 
46.12

 
15.3

Capitation
257

 
24.69

 
8.3

 
211

 
27.60

 
9.1

Direct delivery
43

 
4.14

 
1.4

 
26

 
3.42

 
1.1

Other
64

 
6.18

 
2.0

 
87

 
11.32

 
3.7

 
$
3,110

 
$
298.43

 
100.0
%
 
$
2,322

 
$
302.60

 
100.0
%
 
Year Ended December 31,
 
2015
 
2014
 
Amount
 
PMPM
 
% of
Total
 
Amount
 
PMPM
 
% of
Total
Fee for service
$
8,572

 
$
218.35

 
73.3
%
 
$
5,673

 
$
202.87

 
70.2
%
Pharmacy
1,610

 
41.01

 
13.8

 
1,273

 
45.54

 
15.8

Capitation
982

 
25.02

 
8.4

 
748

 
26.77

 
9.3

Direct delivery
128

 
3.26

 
1.1

 
96

 
3.44

 
1.2

Other
399

 
10.17

 
3.4

 
286

 
10.22

 
3.5

 
$
11,691

 
$
297.81

 
100.0
%
 
$
8,076

 
$
288.84

 
100.0
%
The following table provides the details of the Company’s medical claims and benefits payable as of the dates indicated:
 
December 31,
 
2015
 
2014
Fee-for-service claims incurred but not paid (IBNP)
$
1,191

 
$
871

Pharmacy payable
88

 
71

Capitation payable
37

 
28

Other (1)
266

 
231

 
$
1,582

 
$
1,201

______________________
(1)
“Other” medical claims and benefits payable include amounts payable to certain providers for which the Company acts as an intermediary on behalf of various state agencies without assuming financial risk. Such receipts and payments do not impact the Company’s consolidated statements of income. As of December 31, 2015 and 2014, the Company had recorded non-risk provider payables of approximately $167 million and $119 million, respectively.

-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 13
February 8, 2016

MOLINA HEALTHCARE, INC.
UNAUDITED CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions, except per-member amounts)

The Company’s claims liability includes a provision for adverse claims deviation based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior period” represent the amount by which the Company’s original estimate of claims and benefits payable at the beginning of the period were more than the actual amount of the liability based on information (principally the payment of claims) developed since that liability was first reported. The following table presents the components of the change in medical claims and benefits payable from continuing and discontinued operations combined for the periods indicated:

 
Year Ended
 
December 31,
 
2015
 
2014
 
 
Medical claims and benefits payable, beginning balance
$
1,201

 
$
670

Components of medical care costs related to:
 
 
 
Current period
11,832

 
8,123

Prior period
(141
)
 
(46
)
Total medical care costs
11,691

 
8,077

 
 
 
 
Change in non-risk provider payables
48

 
(32
)
Payments for medical care costs related to:
 
 
 
Current period
10,448

 
7,064

Prior period
910

 
450

Total paid
11,358

 
7,514

Medical claims and benefits payable, ending balance
$
1,582

 
$
1,201

 
 
 
 
Benefit from prior period as a percentage of:
 
 
 
Balance at beginning of period
11.8
%
 
6.9
%
Premium revenue, trailing twelve months
1.1
%
 
0.5
%
Medical care costs, trailing twelve months
1.2
%
 
0.6
%
 
 
 
 
Fee-For-Service Claims Data:
 
 
 
Days in claims payable, fee for service
48

 
49

Number of members at end of year
3,533,000

 
2,623,000

Number of claims in inventory at end of year
380,800

 
307,700

Billed charges of claims in inventory at end of year
$
816

 
$
719

Claims in inventory per member at end of year
0.11

 
0.12

Billed charges of claims in inventory per member at end of year
$
230.91

 
$
273.92

Number of claims received during the year
40,173,300

 
27,597,000

Billed charges of claims received during the year
$
46,211

 
$
30,316




-MORE-


MOH Reports Fourth Quarter and Year-End 2015 Results
Page 14
February 8, 2016


MOLINA HEALTHCARE, INC.
HEALTH INSURER FEE DETAILS BY HEALTH PLAN
(In millions)

 
HIF Reimbursement Revenue, Gross(1)
 
Year Ended December 31, 2015
 
Recognized
 
Necessary for Full Reimbursement
 
Q1 2015
 
 Q2 2015
 
Q3 2015
 
Q4 2015
 
Total
 
2015 HIF:
 
California
$

 
$
17

 
$
6

 
$
8

 
$
31

 
$
31

Florida
2

 
2

 
2

 
2

 
8

 
8

Illinois
1

 
1

 
1

 
1

 
4

 
4

Michigan

 

 
21

 
7

 
28

 
28

New Mexico
7

 
8

 
8

 
7

 
30

 
30

Ohio
12

 
12

 
12

 
12

 
48

 
48

South Carolina
3

 
3

 
3

 
3

 
12

 
12

Texas
6

 
6

 
6

 
5

 
23

 
23

Utah

 

 
4

 
2

 
6

 
6

Washington
11

 
11

 
6

 
9

 
37

 
37

Wisconsin
1

 
1

 
1

 
2

 
5

 
5

Subtotal, Medicaid
43

 
61

 
70

 
58

 
232

 
232

Marketplace

 

 
1

 
1

 
2

 
2

Medicare
6

 
4

 
4

 
5

 
19

 
19

 
49

 
65

 
75

 
64

 
253

 
$
253

2014 HIF:
 
 
 
 
 
 
 
 
 
 
 
California

 
12

 

 

 
12

 
 
Michigan

 

 
7

 

 
7

 
 
Utah

 

 
1

 

 
1

 
 
 
$
49

 
$
77

 
$
83

 
$
64

 
$
273

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recognized in:
 
 
 
 
 
 
 
 
 
 
 
Health insurer fee revenue
$
48

 
$
74

 
$
81

 
$
61

 
$
264

 
 
Premium tax revenue
1

 
3

 
2

 
3

 
9

 
 
 
$
49

 
$
77

 
$
83

 
$
64

 
$
273

 
 
_____________
(1)
Amounts in the table include the Company’s estimate of the full economic impact of the excise tax including premium tax and the income tax effect.

-END-
GRAPHIC 3 molinaa03a01a01a02.jpg begin 644 molinaa03a01a01a02.jpg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end